von Bonin, Frederike

[["dc.bibliographiccitation.firstpage","1548"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.lastpage","1554"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Schoof, Nils"],["dc.contributor.author","von Bonin, Frederike"],["dc.contributor.author","Zeynalova, Samira"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Jung, Werner"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Kube, Dieter"],["dc.date.accessioned","2018-11-07T11:24:31Z"],["dc.date.available","2018-11-07T11:24:31Z"],["dc.date.issued","2009"],["dc.description.abstract","Methods: In 228 DLBCL samples of the German High-Grade Non-Hodgkin's Lymphoma Study Group, the polymorphisms of IL4 (-524CT, rs2243250), IL13 (-1069CT, rs1800925) and IL4R (I75V, rs1805010; S503P, rs1805015; Q576R, rs1801275) were analyzed and the soluble interleukin-4 receptor (sIL4R) serum level was measured before the start of chemotherapy. Results: Patients harboring IL4R V75 (IL4R(I75V-AG) and IL4R(I75V-GG)) had shorter overall survival (OS) (P = 0.044) and event-free survival (EFS) (P = 0.056) periods compared with I75 carriers (IL4R(I75V-AA)). Multivariate analysis adjusted to the International Prognostic Index revealed a relative risk of 1.9 for carriers of the IL4R V75 (P = 0.011) in relation to OS. DLBCL patients homozygous for the IL4R I75 and low sIL4R serum levels have the most favorable OS and EFS. Conclusions: These data support the role for host germline gene variations of immunologically important factors like the IL4R I75V gene variation to predict the survival in DLBCL patients."],["dc.identifier.doi","10.1093/annonc/mdp110"],["dc.identifier.isi","000269955700014"],["dc.identifier.pmid","19515749"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6327"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56423"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","0923-7534"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]